Total Payments
$1.8M
2024 Payments
$236,993
Companies
43
Transactions
2,328
Medicare Patients
22,573
Medicare Billing
$2.4M
Payment Breakdown by Category
Other$975,174 (53.9%)
Consulting$550,047 (30.4%)
Travel$147,618 (8.2%)
Research$90,204 (5.0%)
Food & Beverage$46,082 (2.5%)
Education$104.95 (0.0%)
Gifts$64.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $723,902 | 307 | 40.0% |
| Consulting Fee | $550,047 | 245 | 30.4% |
| Travel and Lodging | $147,618 | 691 | 8.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $121,600 | 38 | 6.7% |
| Unspecified | $90,204 | 17 | 5.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $68,450 | 20 | 3.8% |
| Honoraria | $60,930 | 41 | 3.4% |
| Food and Beverage | $46,082 | 964 | 2.5% |
| Long term medical supply or device loan | $292.59 | 1 | 0.0% |
| Education | $104.95 | 2 | 0.0% |
| Gift | $64.40 | 2 | 0.0% |
Payments by Type
General
$1.7M
2,311 transactions
Research
$90,204
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $481,229 | 787 | $0 (2022) |
| ABBVIE INC. | $243,450 | 261 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $202,241 | 269 | $0 (2021) |
| Aerie Pharmaceuticals, Inc. | $167,295 | 165 | $0 (2021) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $90,567 | 110 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $83,890 | 129 | $0 (2024) |
| Bausch Health US, LLC | $82,212 | 7 | $0 (2019) |
| Glaukos Corporation | $74,434 | 73 | $0 (2024) |
| Alcon Vision LLC | $73,328 | 103 | $0 (2024) |
| Sight Sciences, Inc. | $55,077 | 74 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $236,993 | 305 | Bausch & Lomb Americas Inc. ($61,465) |
| 2023 | $254,603 | 264 | AbbVie Inc. ($120,449) |
| 2022 | $239,632 | 312 | Allergan, Inc. ($76,953) |
| 2021 | $217,357 | 270 | Allergan, Inc. ($124,942) |
| 2020 | $217,996 | 232 | Allergan, Inc. ($111,042) |
| 2019 | $229,134 | 369 | Bausch & Lomb, a division of Bausch Health US, LLC ($59,525) |
| 2018 | $307,890 | 390 | Bausch & Lomb, a division of Bausch Health US, LLC ($102,670) |
| 2017 | $105,690 | 186 | Allergan Inc. ($55,442) |
All Payment Transactions
2,328 individual payment records from CMS Open Payments — Page 1 of 94
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug), MIEBO | Food and Beverage | In-kind items and services | $4.49 | General |
| Category: Ophthalmology | ||||||
| 12/30/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug), MIEBO | Food and Beverage | In-kind items and services | $4.02 | General |
| Category: Ophthalmology | ||||||
| 12/27/2024 | ABBVIE INC. | DURYSTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,025.00 | General |
| Category: EYE CARE | ||||||
| 12/20/2024 | ABBVIE INC. | DURYSTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,025.00 | General |
| Category: EYE CARE | ||||||
| 12/19/2024 | Glaukos Corporation | Radius (Device) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Glaucoma | ||||||
| 12/19/2024 | Sight Sciences, Inc. | OMNI SURGICAL SYSTEM (Device) | Food and Beverage | In-kind items and services | $7.34 | General |
| Category: Ophthalmology | ||||||
| 12/19/2024 | ABBVIE INC. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $5.81 | General |
| Category: EYE CARE | ||||||
| 12/18/2024 | Bausch & Lomb Americas Inc. | VYZULTA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,400.00 | General |
| Category: Ophthalmology | ||||||
| 12/18/2024 | ABBVIE INC. | DURYSTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: EYE CARE | ||||||
| 12/16/2024 | Alcon Vision LLC | Rhopressa (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Ophthalmology | ||||||
| 12/12/2024 | NEW WORLD MEDICAL,INC. | Kahook Dual Blade (Device), Clearpath, Ahmed Glaucoma Valve | Food and Beverage | In-kind items and services | $182.70 | General |
| Category: Ophthalmology | ||||||
| 12/10/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| 12/10/2024 | Thea Pharma Inc. | IYUZEH (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/10/2024 | Alcon Vision LLC | — | Food and Beverage | In-kind items and services | $13.80 | General |
| 12/09/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,850.00 | General |
| Category: Ophthalmology | ||||||
| 12/09/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Travel and Lodging | In-kind items and services | $1,276.39 | General |
| Category: Ophthalmology | ||||||
| 12/09/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Food and Beverage | In-kind items and services | $102.00 | General |
| Category: Ophthalmology | ||||||
| 12/09/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | Cash or cash equivalent | $20.60 | General |
| 12/06/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug), MIEBO | Food and Beverage | In-kind items and services | $22.91 | General |
| Category: Ophthalmology | ||||||
| 12/06/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug), MIEBO | Food and Beverage | In-kind items and services | $11.29 | General |
| Category: Ophthalmology | ||||||
| 12/06/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $10.21 | General |
| Category: Ophthalmology | ||||||
| 12/06/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $5.27 | General |
| Category: Ophthalmology | ||||||
| 12/06/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug), MIEBO | Food and Beverage | In-kind items and services | $1.50 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | Bausch & Lomb Americas Inc. | VYZULTA (Drug) | Travel and Lodging | Cash or cash equivalent | $15.00 | General |
| Category: Ophthalmology | ||||||
| 12/04/2024 | Bausch & Lomb Americas Inc. | VYZULTA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $6,800.00 | General |
| Category: Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Masked, Active-Controlled, Parallel Group, Multi-Center Bioequivalence Study of the Generic Brinzolamide 1 Ophthalmic Suspension Compared to Reference Listed Drug Azopt Brinzolamide Ophthalmic Suspension 1 in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension. | Bausch Health US, LLC | $70,600 | 6 |
| A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED, PARALLEL GROUP, MULTI-CENTER BIOEQUIVELENCE STUDY OF THE GENERIC BRINZOLAMIDE 1 OPHTHALMIC SUSPENSION COMPARED TO BRANDED BRINZOLAMIDE 1 OPHTHALMIC SUSPENSION AZOPT IN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION | Bausch Health US, LLC | $11,612 | 1 |
| TOPCON MAESTRO2 OCT ANGIOGRAPHY SOFTWARE EVALUATION STUDY | TOPCON MEDICAL SYSTEMS, INC. | $2,800 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,527 | 6 |
| Triton Reference Data Base and Triton Agreement and Precision Study | TOPCON CORPORATION | $1,400 | 1 |
| TRITON OCT A SOFTWARE PRE-STUDY AND SOFTWARE EVALUATION STUDY | TOPCON CORPORATION | $1,000 | 1 |
| Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 | Glaukos Corporation | $264.70 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 5,356 | 6,896 | $2.0M | $583,340 |
| 2022 | 28 | 5,725 | 7,298 | $2.0M | $592,325 |
| 2021 | 31 | 5,982 | 7,990 | $2.1M | $658,524 |
| 2020 | 30 | 5,510 | 6,836 | $1.8M | $520,491 |
Total Patients
22,573
Total Services
29,020
Medicare Billing
$2.4M
Procedure Codes
116
All Medicare Procedures & Services
116 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 1,255 | 2,159 | $436,118 | $155,910 | 35.7% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 712 | 731 | $205,411 | $72,239 | 35.2% |
| 66984 | Removal of cataract with insertion of prosthetic lens | Facility | 2023 | 96 | 160 | $332,776 | $56,009 | 16.8% |
| J7351 | Injection, bimatoprost, intracameral implant, 1 microgram | Office | 2023 | 20 | 310 | $155,000 | $50,126 | 32.3% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 633 | 671 | $95,953 | $34,019 | 35.5% |
| 65855 | Laser repair to improve eye fluid flow | Office | 2023 | 76 | 107 | $120,268 | $22,269 | 18.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 208 | 220 | $60,500 | $21,792 | 36.0% |
| 92133 | Imaging of optic nerve | Office | 2023 | 685 | 706 | $71,306 | $21,140 | 29.6% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Facility | 2023 | 67 | 73 | $84,300 | $20,803 | 24.7% |
| 66174 | Dilation of fluid outflow drainage within eye | Facility | 2023 | 25 | 36 | $57,600 | $18,926 | 32.9% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 147 | 147 | $49,098 | $17,012 | 34.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 210 | 234 | $45,630 | $16,630 | 36.4% |
| 66982 | Complex removal of cataract with insertion of prosthetic lens | Facility | 2023 | 17 | 23 | $61,035 | $13,722 | 22.5% |
| 92134 | Imaging of retina | Office | 2023 | 353 | 375 | $37,875 | $12,553 | 33.1% |
| 66250 | Revision or repair of operative wound of eye | Office | 2023 | 11 | 12 | $12,456 | $8,008 | 64.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 60 | 60 | $21,360 | $7,783 | 36.4% |
| 92020 | Exam of the internal drainage system of eye | Office | 2023 | 307 | 312 | $21,528 | $6,943 | 32.3% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2023 | 125 | 177 | $25,356 | $6,004 | 23.7% |
| 66710 | Destruction of lens tissue using laser | Facility | 2023 | 15 | 19 | $21,356 | $5,952 | 27.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 95 | 112 | $14,000 | $5,360 | 38.3% |
| 66030 | Injection of medication into eye | Office | 2023 | 20 | 31 | $15,845 | $4,960 | 31.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 28 | 28 | $6,580 | $2,187 | 33.2% |
| 92250 | Photography of the retina | Office | 2023 | 47 | 48 | $4,896 | $1,433 | 29.3% |
| 76514 | Ultrasound scan of cornea to determine thickness | Office | 2023 | 119 | 119 | $3,927 | $1,088 | 27.7% |
| 92071 | Fitting of contact lens for treatment of eye surface disease | Office | 2023 | 14 | 14 | $840.00 | $451.22 | 53.7% |
About Dr. Jason Bacharach, MD
Dr. Jason Bacharach, MD is a Ophthalmology healthcare provider based in Petaluma, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1639160112.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jason Bacharach, MD has received a total of $1.8M in payments from pharmaceutical and medical device companies, with $236,993 received in 2024. These payments were reported across 2,328 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($723,902).
As a Medicare-enrolled provider, Bacharach has provided services to 22,573 Medicare beneficiaries, totaling 29,020 services with total Medicare billing of $2.4M. Data is available for 4 years (2020–2023), covering 116 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Glaucoma Specialist
- Location Petaluma, CA
- Active Since 11/02/2005
- Last Updated 03/07/2023
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1639160112
Products in Payments
- DURYSTA (Drug) $385,822
- VYZULTA (Drug) $259,888
- LUMIGAN (Drug) $134,359
- Rhopressa (Drug) $89,254
- BRINZOLAMIDE (Drug) $70,600
- Cequa (Drug) $63,289
- Rocklatan (Drug) $60,567
- VUITY (Drug) $54,453
- rocklatan (Drug) $54,017
- IYUZEH (Drug) $40,026
- RESTASIS (Drug) $37,045
- rhopressa (Drug) $36,844
- MIEBO (Drug) $35,884
- iDose (Device) $34,604
- DEXYCU (Drug) $33,192
- OMNI(R) SURGICAL SYSTEM (US) (Device) $32,955
- TRAVATAN Z (Drug) $31,402
- CEQUA (Drug) $23,578
- OMNI SURGICAL SYSTEM (Device) $21,508
- iStent infinite Trabecular Micro-Bypass System Model iS3 (Device) $14,000
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.